# V1 Empirics Check — openai/gpt-oss-120b (Variant C)

**Model:** openai/gpt-oss-120b
**Variant:** C
**Date:** 2026-03-13T17:59:50.776727

---

**1. Idea Fidelity**  
The paper follows the core of the original manifest: it exploits the staggered rollout of state‑wide mandatory electronic prescribing for controlled substances (EPCS) to estimate causal effects on opioid‑overdose mortality, and it decomposes the outcome by ICD‑10 subtype (prescription opioids T40.2, synthetic opioids T40.4, heroin T40.1) as a built‑in mechanism/​placebo test.  

What is *missing*:  

* The manifest also proposed a secondary analysis of Medicaid prescription‑volume data (SDUD) to show whether EPCS actually reduces the number of prescriptions written. The manuscript does **not** present any evidence on prescription volumes, leaving the “mechanism” claim untested on the supply side.  
* The original plan mentioned leave‑one‑out (state‑by‑state) checks and a “minimum‑detectable‑effect” power analysis. The paper reports several robustness checks but does not show a systematic leave‑one‑out exercise or a transparent power calculation.  
* The timing of treatment is treated at the calendar‑year level even for states whose mandates took effect mid‑year (e.g., NY Mar 2016, VA Jul 2020). The manifest suggested a more granular approach would be preferable.  

Overall the paper captures the spirit of the idea but omits two substantive components that would strengthen the link between the policy, its supply‑side channel, and mortality outcomes.

---

**2. Summary**  
The study uses a Callaway–Sant’Anna staggered difference‑in‑differences estimator on state‑year CDC provisional overdose‑mortality data (2015‑2023) to assess whether mandatory EPCS reduced opioid deaths. The author finds no statistically significant impact on prescription‑opioid deaths (T40.2), synthetic‑opioid deaths (T40.4), heroin deaths (T40.1), or total opioid mortality, and the null result is robust to a variety of specifications and placebo outcomes.

---

**3. Essential Points**  

1. **Identification Threats from Concurrent Policies** – Many states that adopted EPCS around 2020‑2022 simultaneously tightened PDMPs, imposed prescribing limits, or expanded naloxone access. Without controlling for these co‑occurring reforms, the ATT may be biased either upward or downward. A credible identification strategy should either (a) include state‑specific policy controls, (b) restrict the sample to periods before other major reforms, or (c) employ a triple‑difference design that isolates the EPCS channel.  

2. **Statistical Power and Minimum Detectable Effect** – The standard error of the baseline estimate (≈0.83 per 100 k) yields an 80 % power detectable effect of about 2.3 deaths per 100 k, roughly 50 % of the mean prescription‑opioid rate. This is a relatively large MDE, so the study may be under‑powered to detect modest but policy‑relevant reductions. The manuscript should explicitly present a power calculation, discuss whether the null is a true zero or simply “cannot be ruled out” given the data, and explore ways to increase power (e.g., using monthly rather than annual data, or employing a synthetic‑control approach for high‑adoption states).  

3. **Treatment Timing and Exposure Measurement** – Assigning the entire calendar year as “treated” for states whose mandates started mid‑year inflates exposure and potentially attenuates the estimated effect. A more precise specification (e.g., a fractional treatment variable based on the number of months the mandate was active, or a month‑level DiD) would reduce measurement error. The paper currently lacks any sensitivity test to this choice.  

If these three issues cannot be remedied, the credibility of the null finding is seriously compromised. The paper should therefore be **revised** rather than rejected outright.

---

**4. Suggestions**  

Below are concrete, non‑essential but highly valuable recommendations that will help the author turn a promising null result into a compelling contribution.

| Area | Recommendation | Rationale / Implementation |
|------|----------------|-----------------------------|
| **Data granularity** | Switch from annual to **monthly** death counts. The CDC VSRR provides month‑by‑month provisional counts; using them will (i) increase the number of observations (≈5,500 state‑months), (ii) sharpen the timing of treatment, and (iii) allow richer event‑study dynamics (e.g., separate leads/lags up to 12 months). | The author already extracts month‑level data for the VSRR; the main task is to re‑aggregate to a balanced panel and adjust standard errors for serial correlation (e.g., use two‑way clustering or Driscoll‑Kraay). |
| **Co‑occurring policies** | Compile a policy‑track dataset (e.g., PDMP mandatory use, prescribing limits, naloxone laws, Medicaid expansion) from sources such as the Prescription Drug Policy Project or the CDC’s Opioid Policy Tracker. Include these as **state‑year controls** or interact them with the treatment indicator. | This will address the main identification threat. A simple “policy index” (sum of active reforms) can be a start; a more refined approach uses separate dummies for each reform. |
| **Triple‑difference / mechanism test** | Use Medicaid prescription‑volume data (SDUD) as a **second outcome**. Estimate (i) effect on total opioid prescriptions, (ii) effect on “high‑dose” prescriptions, (iii) test whether any reduction in prescriptions translates into mortality changes. This will directly verify the supply‑side channel that the policy is supposed to affect. | The SDUD dataset is already mentioned in the manifest; linking it to the same state‑year panel is straightforward. A 2‑step DiD (first stage on prescriptions, second stage on mortality) can be reported. |
| **Leave‑one‑out robustness** | Conduct a **state‑by‑state jackknife**: re‑estimate the ATT after dropping each treated state in turn. Plot the distribution of estimates to see whether a single state (e.g., New York) drives the result. | The paper already drops New York in one specification; a systematic jackknife provides a fuller picture and strengthens the claim that the null is not driven by a particular early adopter. |
| **Alternative inference** | Complement state‑clustered SEs with **wild cluster bootstrap** (as done) but also with **randomization inference** à la Conley and Tabord-Meehan, especially given the modest number of treated clusters (31). Report both p‑values. | This will reassure readers that inference is robust to the limited number of clusters and to possible serial correlation. |
| **Event‑study visualization** | Populate the empty Table 5 with a **graph of ATT vs. event time** (−5 to +5 years). Include 95 % confidence bands. Highlight the pre‑trend window to make the parallel‑trends assumption transparent. | Visual evidence is more convincing than a table of coefficients with many blanks; a plot can also reveal any delayed effects (e.g., a gradual decline after 2 years). |
| **Power analysis** | Add a **formal power calculation** (e.g., using `powerDiD` or Monte‑Carlo simulations) that shows the minimum detectable effect given the observed variance, number of clusters, and treatment timing. Discuss policy relevance of effects smaller than the MDE. | This directly tackles the concern that the null may be due to insufficient power and helps readers gauge the practical significance of the findings. |
| **Treatment coding** | Implement a **fractional treatment variable**: treat a state as 0.5 treated in the year of implementation if the mandate began in July, 0 otherwise for the prior months. Compare results to the binary‑year specification. | This will demonstrate that the null is not driven by the coarse treatment definition. |
| **ICD‑10 code overlap** | Clarify that deaths can appear in multiple categories (e.g., a heroin‑fentanyl mix). Consider constructing **mutually exclusive** categories (e.g., “prescription‑only”, “synthetic‑only”, “mixed”) to avoid double‑counting and to better isolate the prescription channel. | This improves interpretability of the subtype decomposition and may affect the magnitude of the ATT for each channel. |
| **Discussion of external validity** | Expand the discussion to include how the results may differ for **states that already had high EPCS adoption before mandates** (e.g., those with large pharmacy chains). If the marginal effect is small because most prescribers were already electronic, the policy implication changes. | This contextualizes the null and helps policymakers understand whether the result is a failure of the mandate per se or of its timing. |
| **Alternative outcomes** | Explore **non‑fatal overdose** (e.g., EMS calls, emergency‑department visits) if data are available. Mortality may be too noisy or lagged to capture early impacts. | A broader set of outcomes can uncover short‑run effects that mortality data miss. |
| **Appendix clarity** | Add a **table of treated‑state adoption dates** (year, month) and a **summary of never‑treated states**. Provide the exact list of policy controls used. | Transparency aids reproducibility and lets reviewers verify the treatment definition. |
| **Stylistic / editorial** | – Remove the “Autonomous Research” boilerplate from the author line, or place it in a footnote. – Ensure all citations are up‑to‑date (e.g., the RAND review should have a 2024 date). – Include a short “Limitations” subsection that explicitly lists the three concerns above. | Improves readability and aligns with AER Insights formatting. |

Implementing the majority of these suggestions will not only shore up the internal validity of the causal estimate but also enrich the paper’s contribution by showing *why* the policy does (or does not) work. The central claim—that mandatory EPCS did not move the needle on opioid mortality—remains interesting, especially given the large policy investment; however, without addressing the identification and power issues, readers may dismiss the result as an artifact of insufficient variation. By tightening the empirical design, adding a supply‑side test, and communicating statistical power transparently, the manuscript will become a solid, policy‑relevant addition to the opioid‑policy literature.
